Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
argenx SE stock logo
ARGX
argenx
$576.74
-0.7%
$586.57
$361.26
$678.21
$35.22B0.57323,511 shs350,163 shs
BioNTech SE stock logo
BNTX
BioNTech
$95.71
-4.5%
$97.44
$76.53
$131.49
$23.01B1.35913,559 shs1.49 million shs
Beigene, Ltd. stock logo
ONC
Beigene
$246.04
-0.3%
$239.92
$141.31
$287.88
$24.48B0.35458,911 shs406,953 shs
Qiagen stock logo
QGEN
Qiagen
$45.13
+0.3%
$41.70
$37.63
$49.30
$10.03B0.671.17 million shs2.52 million shs
The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
argenx SE stock logo
ARGX
argenx
-0.72%-1.85%-10.60%-7.67%+52.67%
BioNTech SE stock logo
BNTX
BioNTech
-4.53%-3.01%-8.10%-15.24%+2.66%
Beigene, Ltd. stock logo
ONC
Beigene
-0.26%+1.91%-5.30%-9.48%+24,603,999,900.00%
Qiagen stock logo
QGEN
Qiagen
+0.50%+7.28%+5.47%+17.77%+9.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
argenx SE stock logo
ARGX
argenx
3.2742 of 5 stars
3.52.00.00.03.61.71.9
BioNTech SE stock logo
BNTX
BioNTech
2.648 of 5 stars
4.42.00.00.03.10.80.0
Beigene, Ltd. stock logo
ONC
Beigene
3.2696 of 5 stars
4.50.00.00.03.01.70.6
Qiagen stock logo
QGEN
Qiagen
3.2531 of 5 stars
1.22.01.74.52.81.71.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
argenx SE stock logo
ARGX
argenx
3.05
Buy$709.1822.96% Upside
BioNTech SE stock logo
BNTX
BioNTech
2.83
Moderate Buy$140.1446.43% Upside
Beigene, Ltd. stock logo
ONC
Beigene
3.00
Buy$319.0029.65% Upside
Qiagen stock logo
QGEN
Qiagen
2.30
Hold$48.427.28% Upside

Current Analyst Ratings Breakdown

Latest QGEN, ARGX, ONC, and BNTX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/29/2025
BioNTech SE stock logo
BNTX
BioNTech
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy ➝ Neutral$110.00
5/22/2025
BioNTech SE stock logo
BNTX
BioNTech
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$120.00 ➝ $116.00
5/22/2025
BioNTech SE stock logo
BNTX
BioNTech
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$134.00 ➝ $134.00
5/21/2025
argenx SE stock logo
ARGX
argenx
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
5/14/2025
BioNTech SE stock logo
BNTX
BioNTech
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$145.00 ➝ $134.00
5/14/2025
argenx SE stock logo
ARGX
argenx
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$699.00
5/14/2025
argenx SE stock logo
ARGX
argenx
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform
5/13/2025
argenx SE stock logo
ARGX
argenx
Baird R W
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Strong-Buy
5/13/2025
argenx SE stock logo
ARGX
argenx
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Outperform$680.00 ➝ $680.00
5/9/2025
argenx SE stock logo
ARGX
argenx
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$704.00 ➝ $708.00
5/9/2025
argenx SE stock logo
ARGX
argenx
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$1,100.00 ➝ $1,065.00
(Data available from 5/31/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
argenx SE stock logo
ARGX
argenx
$2.58B13.65N/AN/A$69.22 per share8.33
BioNTech SE stock logo
BNTX
BioNTech
$2.75B8.38$4.12 per share23.25$92.17 per share1.04
Beigene, Ltd. stock logo
ONC
Beigene
$4.18B5.85N/AN/A$37.10 per share6.63
Qiagen stock logo
QGEN
Qiagen
$2.00B5.01$3.76 per share12.01$16.08 per share2.81
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
argenx SE stock logo
ARGX
argenx
-$295.05M$16.21N/A53.16N/A-2.11%-1.45%-1.29%7/24/2025 (Estimated)
BioNTech SE stock logo
BNTX
BioNTech
$1.01B-$3.40N/AN/AN/A-15.16%-2.35%-2.05%8/4/2025 (Estimated)
Beigene, Ltd. stock logo
ONC
Beigene
-$881.71M-$3.72N/A346.547.73-25.94%-25.12%-14.95%N/A
Qiagen stock logo
QGEN
Qiagen
$83.59M$0.40125.6618.352.394.23%13.92%8.40%7/30/2025 (Estimated)

Latest QGEN, ARGX, ONC, and BNTX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2025Q1 2025
argenx SE stock logo
ARGX
argenx
$2.32$2.58+$0.26$2.58$748.34 million$1.35 billion
5/7/2025Q1 2025
Beigene, Ltd. stock logo
ONC
Beigene
-$0.71$1.22+$1.93$0.01$1.12 billion$1.12 billion
5/7/2025Q1 2025
Qiagen stock logo
QGEN
Qiagen
$0.50$0.55+$0.05$0.41$465.66 million$483.46 million
3/10/2025Q4 2024
BioNTech SE stock logo
BNTX
BioNTech
$0.38$1.08+$0.70$1.15$1.24 billion$1.19 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
argenx SE stock logo
ARGX
argenx
N/AN/AN/AN/AN/A
BioNTech SE stock logo
BNTX
BioNTech
$1.531.60%N/AN/A N/A
Beigene, Ltd. stock logo
ONC
Beigene
N/AN/AN/AN/AN/A
Qiagen stock logo
QGEN
Qiagen
$0.250.55%N/A62.50%N/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
argenx SE stock logo
ARGX
argenx
N/A
8.53
7.88
BioNTech SE stock logo
BNTX
BioNTech
0.01
7.33
7.21
Beigene, Ltd. stock logo
ONC
Beigene
0.05
1.93
1.72
Qiagen stock logo
QGEN
Qiagen
0.38
3.61
3.09

Institutional Ownership

CompanyInstitutional Ownership
argenx SE stock logo
ARGX
argenx
60.32%
BioNTech SE stock logo
BNTX
BioNTech
15.52%
Beigene, Ltd. stock logo
ONC
Beigene
48.55%
Qiagen stock logo
QGEN
Qiagen
70.00%

Insider Ownership

CompanyInsider Ownership
argenx SE stock logo
ARGX
argenx
2.43%
BioNTech SE stock logo
BNTX
BioNTech
19.20%
Beigene, Ltd. stock logo
ONC
Beigene
6.62%
Qiagen stock logo
QGEN
Qiagen
9.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
argenx SE stock logo
ARGX
argenx
65061.06 million59.29 millionOptionable
BioNTech SE stock logo
BNTX
BioNTech
3,080240.39 million193.71 millionOptionable
Beigene, Ltd. stock logo
ONC
Beigene
9,00099.25 million90.59 millionN/A
Qiagen stock logo
QGEN
Qiagen
6,030222.29 million201.89 millionOptionable

Recent News About These Companies

Equities Analysts Offer Predictions for Qiagen Q2 Earnings
Qiagen stock logo
Qiagen (NYSE:QGEN) Releases FY 2025 Earnings Guidance
Contrasting Genfit (NASDAQ:GNFT) and Qiagen (NYSE:QGEN)

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
argenx stock logo

argenx NASDAQ:ARGX

$576.74 -4.21 (-0.72%)
Closing price 05/30/2025 04:00 PM Eastern
Extended Trading
$573.31 -3.43 (-0.59%)
As of 05/30/2025 05:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

BioNTech stock logo

BioNTech NASDAQ:BNTX

$95.71 -4.54 (-4.53%)
Closing price 05/30/2025 04:00 PM Eastern
Extended Trading
$96.12 +0.42 (+0.43%)
As of 05/30/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.

Beigene stock logo

Beigene NASDAQ:ONC

$246.04 -0.64 (-0.26%)
As of 05/30/2025 04:00 PM Eastern

BeiGene Ltd. Is a global oncology company, which engages in providing pharmaceutical products. Its medicines include BRUKINSA, TEVIMBRA, and PARTRUVIX. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY.

Qiagen stock logo

Qiagen NYSE:QGEN

$45.13 +0.13 (+0.29%)
Closing price 05/30/2025 03:59 PM Eastern
Extended Trading
$45.14 +0.00 (+0.01%)
As of 05/30/2025 04:44 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. The firm assay technologies make these biomolecules visible and ready for analysis. Its bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996, and is headquartered in Venlo, the Netherlands.